Tscan Therapeutics Stock Market Value
| TCRX Stock | USD 4.26 0.32 8.12% |
| Symbol | Tscan |
Tscan Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tscan Therapeutics. If investors know Tscan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tscan Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share 0.175 | Quarterly Revenue Growth (0.73) | Return On Assets (0.23) | Return On Equity (0.56) |
The market value of Tscan Therapeutics is measured differently than its book value, which is the value of Tscan that is recorded on the company's balance sheet. Investors also form their own opinion of Tscan Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tscan Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tscan Therapeutics' market value can be influenced by many factors that don't directly affect Tscan Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tscan Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tscan Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tscan Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Tscan Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Tscan Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Tscan Therapeutics.
| 12/03/2022 |
| 11/22/2024 |
If you would invest 0.00 in Tscan Therapeutics on December 3, 2022 and sell it all today you would earn a total of 0.00 from holding Tscan Therapeutics or generate 0.0% return on investment in Tscan Therapeutics over 720 days. Tscan Therapeutics is related to or competes with Apellis Pharmaceuticals, Iteos Therapeutics, Day One, Acumen Pharmaceuticals, X4 Pharmaceuticals, Inozyme Pharma, and Cognition Therapeutics. TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell ther... More
Tscan Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Tscan Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Tscan Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.19) | |||
| Maximum Drawdown | 17.54 | |||
| Value At Risk | (5.05) | |||
| Potential Upside | 5.22 |
Tscan Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tscan Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Tscan Therapeutics' standard deviation. In reality, there are many statistical measures that can use Tscan Therapeutics historical prices to predict the future Tscan Therapeutics' volatility.| Risk Adjusted Performance | (0.12) | |||
| Jensen Alpha | (0.77) | |||
| Total Risk Alpha | (1.00) | |||
| Treynor Ratio | (0.27) |
Tscan Therapeutics Backtested Returns
Tscan Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.11, which indicates the firm had a -0.11% return per unit of risk over the last 3 months. Tscan Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Tscan Therapeutics' Risk Adjusted Performance of (0.12), coefficient of variation of (619.37), and Variance of 11.61 to confirm the risk estimate we provide. The entity has a beta of 2.09, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Tscan Therapeutics will likely underperform. At this point, Tscan Therapeutics has a negative expected return of -0.38%. Please make sure to validate Tscan Therapeutics' coefficient of variation, value at risk, as well as the relationship between the Value At Risk and rate of daily change , to decide if Tscan Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.08 |
Very weak reverse predictability
Tscan Therapeutics has very weak reverse predictability. Overlapping area represents the amount of predictability between Tscan Therapeutics time series from 3rd of December 2022 to 28th of November 2023 and 28th of November 2023 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Tscan Therapeutics price movement. The serial correlation of -0.08 indicates that barely 8.0% of current Tscan Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.08 | |
| Spearman Rank Test | -0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 1.41 |
Tscan Therapeutics lagged returns against current returns
Autocorrelation, which is Tscan Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Tscan Therapeutics' stock expected returns. We can calculate the autocorrelation of Tscan Therapeutics returns to help us make a trade decision. For example, suppose you find that Tscan Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Tscan Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Tscan Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Tscan Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Tscan Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Tscan Therapeutics Lagged Returns
When evaluating Tscan Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Tscan Therapeutics stock have on its future price. Tscan Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Tscan Therapeutics autocorrelation shows the relationship between Tscan Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Tscan Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.